GeneDx Holdings Corp. (WGS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
GeneDx delivered a strong Q2 2025, with revenues and earnings beating expectations and full-year guidance raised over 10%. Revenue growth is driven by higher testing volumes, improved reimbursement rates, and a continued decline in denial rates. Momentum is building for 30%+ test volume growth in 2025, supported by testing for new indications, integration with Epic systems at hospitals, and Medicaid coverage.
GeneDx Holdings Corp. (WGS) Q2 2025 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Katherine A. Stueland - President, CEO & Director Kevin Feeley - Chief Financial Officer Sabrina Dunbar - Corporate Participant Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Daniel Gregory Brennan - TD Cowen, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Mark Anthony Massaro - BTIG, LLC, Research Division Subhalaxmi T.
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to a loss of $0.11 per share a year ago.
Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again
GENEDX HOLDINGS (WGS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Exome and Genome Growth Boost WGS' Q2 Earnings?
GeneDx is likely to have experienced a Q2 lift, backed by strong Exome and genome test volumes, new indications and strategic tech moves.
GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does GENEDX HOLDINGS (WGS) Have the Potential to Rally 26.17% as Wall Street Analysts Expect?
The mean of analysts' price targets for GENEDX HOLDINGS (WGS) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GeneDx: Strong Testing Volume And An Invaluable Genomic Database
GeneDx leverages a vast rare disease database and advanced genomic testing, offering superior insights over traditional panel testing. The company achieved a significant turnaround, becoming cash flow positive in Q4 2024 and Q1 2025 after years of net losses. Strategic restructuring, including shutting down Sema4's reproductive health unit, streamlined costs and sharpened focus on WGS's core strengths.
GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Predict a 32.62% Upside in GENEDX HOLDINGS (WGS): Here's What You Should Know
The consensus price target hints at a 32.6% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GeneDx: Strong Fundamentals Intact As Market Misreads Test Volume Dip
GeneDx delivered strong Q1 2025 results, beating revenue and EPS estimates, and raised full-year guidance despite a minor sequential test volume dip. The volume decline is attributable to seasonality, adverse weather, and one fewer business day, not a structural slowdown; fundamentals remain robust. Strong pricing power and rising reimbursement rates drive revenue growth, setting a solid foundation for future acceleration as volumes rebound.
